

Title:

“Hypo-methylation mediates Chromosomal Instability in pancreatic NET”

Authors:

I. Marinoni^{§1}, A. Wiederkeher¹, T. Wiedmer¹, S. Pantasis¹, A. Di Domenico¹, R. Frank¹, E. Vassella¹, A. Schmitt¹, and A. Perren¹.

[§] Corresponding author

Ilaria.marinoni@pathology.unibe.ch

Institute of Pathology, University of Bern, Murtenstrasse 31, 3010 Bern Switzerland.

Authors' affiliation:

Institute of Pathology, University of Bern, Murtenstrasse 31, 3010 Bern Switzerland.

Short title:

Methylation and genomic instability in PanNET

Keywords: Pancreatic Neuro-Endocrine Tumors, DNA methylation, Chromosomal Instability, DAXX and ATRX.

Word count: 5720

Summary:

DAXX and or ATRX loss occur in 40% of Pancreatic Neuro-endocrine Tumors (PanNETs). PanNETs negative for DAXX or ATRX show an increased risk of relapse. The tumor-associated pathways activated upon DAXX or ATRX loss and how this event may induce Chromosomal Instability (CIN) and Alternative Lengthening Telomeres (ALT) are still unknown. Both DAXX and ATRX are involved in DNA methylation regulation. DNA methylation of heterochromatin and of non-coding sequences is extremely important for the maintenance of genomic stability. We analysed the association of DAXX and or ATRX loss and CIN with global DNA methylation in human PanNET samples and the effect of DAXX knock down on methylation and cell proliferation.

We assessed *LINE1* as well as global DNA methylation in 167 PanNETs and we found that DAXX and or ATRX negative tumors and tumors with CIN were hypo-methylated. DAXX knock-down in PanNET cell lines blocked cells in G1/G0 phase and seemed to increase CIN in QGP-1 cells. However, no direct changes in DNA methylation were observed after DAXX knock down *in vitro*.

In conclusion our data indicate that epigenetic changes are crucial steps in the progression of PanNETs loss and suggest that DNA methylation is the mechanism via which CIN is induced, allowing clonal expansion and selection.

Introduction

The molecular pathways and mechanisms underlying initiation and progression of pancreatic neuroendocrine tumors (PanNET) are still poorly understood. Mutations in *DAXX* (Death Domain Associated Protein) and *ATRX* (ATR-X) with correspondent loss of protein expression in the tumor tissue occur in 40% of PanNETs (Jiao, et al. 2011). *DAXX* and or *ATRX* loss correlates with Chromosomal Instability (CIN) and predicts for relapse in low stage patients (Stage I to III in the absence of distant metastasis) (Marinoni, et al. 2014). *DAXX* and or *ATRX* negative tumors show Alternative Lengthening of Telomeres (ALT), a telomerase independent mechanism for telomere length maintenance, based on homologous recombination (Heaphy, et al. 2011). The mechanisms and the sequence of events linking *DAXX/ATRX* mutation, ALT and CIN are unknown.

In addition to mutations, the importance of epigenetic changes is increasingly recognized for many cancer types (reviewed in (Das and Singal 2004). *DAXX* and *ATRX* participate in maintaining the epigenetic status of the cells by regulating both DNA methylation and H3.3 deposition at telomeric and peri-centromeric regions. *DAXX* interacts and recruits DNA methyltransferase enzyme 1 (DNMT1) to specific promoters including *RASSF1* and *RELB* (Puto and Reed 2008). *ATRX* contains the ADD domain as does DNMT3-DNMT3L, important for establishing and maintaining DNA methylation pattern (Noh, et al. 2016).

Impairment of DNA methylation in PanNETs has been shown in several genes (*VHL*, *cdkn2a* (p16), *RASSF1*, *DAPK1*, *TIMP3*, *PAX5*, *HIC1*, *CADMI*, *PYCARD*, *ESR1*, *VHL*, *RARB*, *WT1* and *MGMT*). (House, et al. 2003; Malpeli, et al. 2011; Schmitt, et al. 2014; Schmitt, et al. 2009; Stefanoli, et al. 2014). Genome wide methylation profiling of PanNET has shown a difference of methylation pattern between *DAXX* and *ATRX* negative tumors, suggesting that mainly *DAXX* loss is driving DNA methylation changes in PanNETs (Pipinikas, et al. 2015).

DNA methylation not only regulates gene expression, but also genomic stability. Indeed heterochromatin and silenced regions are usually hyper-methylated resulting in a highly condensed chromatin structure not accessible to the transcription machinery. Hypo-methylated DNA regions are usually highly transcribed. Repetitive and mobile elements such *LINE1* (Long Interspersed Element-1) and *ALU* (*Arthrobacter luteus*) sequences are preserved from transcription and activation by DNA hyper-methylation. Once activated, these sequences move within the genome and thereby generate chromosomal instability. Hypo-methylation of *LINE1* and *ALU* sequences occurs in several tumors including PanNETs (Choi, et al. 2007; Stefanoli et al. 2014). It is currently unknown whether *LINE1* and *ALU* hypo-methylation is directly linked to *DAXX* and or *ATRX* mutation. Regulation of transcription of the telomeric sequences TERRA (Telomeric repeat containing RNA) and telomere stability is also dependent on the DNA methylation status. Dnmt1 deficient mouse embryonic stem cells show elongated telomeres, increased recombination at telomeric regions and ALT activation (Gonzalo, et al. 2006).

In the present study we aimed to analyse the effect of *DAXX* and or *ATRX* loss on global methylation in ex-vivo human PanNETs samples and *in vitro* in BON-1 and QGP-1 cell line-models. *In vitro* we also assessed genomic instability induction upon *DAXX* knock down. We found that *DAXX* and or *ATRX* negative PanNETs showed global hypo-methylation but not *LINE1* hypo-methylation compare to positive tumors. Additionally we were able to find a link between *LINE1* hypo-methylation and CIN in PanNETs. *DAXX* knock down does not induce methylation changes in BON-1 and QGP-1 cells.

Material and Methods

Human samples

167 out of 207 resected well differentiated PanNETs (G1-G2) and 11 matching control were used

in the study based on DNA viability and informative IHC results (Marinoni et al. 2014).
CIN data obtained by Comparative Genomic Hybridization (CGH) were previously reported
(Marinoni et al. 2014).
CIN were defined as showing a total number of gains and losses of 8 or more in conventional
CGH and of 20 or more in array CGH. The use of patient material was approved by the local
ethics committees (Number 105/2015). The composition of samples is described in table 1 and in
the supplementary figure 1.

Cell line culture conditions and treatments

The pancreatic neuroendocrine cell line BON-1 (pancreatic carcinoid) was provided by E.J.
Speel, Department of Pathology, Maastricht, The Netherlands and metastatic somatostatinoma
derived QGP-1 cell line was obtained from Japanese Health Sciences Foundation, Osaka, Japan.
Both cell lines authentication was performed by STRs analysis (Mycrosynth, Balgach,
Switzerland) upon arrival (2011) and in the present year. QGP-1 cells resulted 100% matching
with the QGP-1 profile (GNE586559, Genentech, Roche, Basel, Switzerland). BON-1 cells are
not commercially available therefore no comparison is possible, however STRs analysis of these
cells revealed no matching with any data available in the ATCC database, excluding any
contamination with other cell lines. Additionally the expression of the neuro-endocrine markers
Synaptophysin and Chromogranin-A was checked yearly. Both QGP-1 and BON-1 cells express
the two markers. Cells were kept in culture for a maximum of 20-25 passages.
Both cell lines were cultured at 37°C under 5% CO₂. BON-1 were cultured in DMEM/Nutrient
Mixture F-12 Ham (D6421, Sigma-Aldrich, Buchs SG, Switzerland) and QGP-1 in RPMI 1640
Dutch modification (R7638, Sigma-Aldrich), both media supplemented with 10% FBS (GIBCO,

Thermo Fisher Scientific, Paisley, UK), 2nM L-alanyl-L-glutamin (Sigma-Aldrich), 100µg/ml streptomycin and 100units/ml of penicillin (Sigma-Aldrich).

Immuno-histo-chemistry (IHC)

Four-micrometer sections were taken from a TMA including 207 pNETs derived from patients who underwent surgery at the Inselspital Bern, Switzerland previously described (Marinoni et al. 2014) and stained with an anti-5-methylcytidine antibody BI_MECY_0100 (Eurogentec, Kaneka, Liege, Belgium). The Immunohistochemical staining was performed on an automated staining system (Leica Bond III; Leica Biosystems, Nunningen, Switzerland). Antigen retrieval was performed by heating citrate buffer at 100° for 30 minutes. The primary antibody was incubated for 30 minutes at a dilution of 1:200. Visualization was performed using the avidin-biotin complex method, which yielded a brown staining signal. Normal pancreatic islets show strong positive staining indicating a certain level of DNA methylation thus we scored as high-methylated samples showing similar or stronger staining than normal islets and low-methylated samples showing weaker staining. To exclude false-negative samples, only samples with positive nuclear staining of non-neoplastic cells and negative tumor nuclei were scored as negative (153 of 207 samples remaining informative). 54 Samples with both negative tumor nuclei and non-neoplastic stromal and endothelial cells were scored as non-informative and excluded from further analysis.

DNA extraction, bisulfite conversion and global methylation analysis

DNA was extracted from cell pellet of about 6×10^5 cells or from paraffin embedded human PanNETs (55 tumor samples with more than 80% tumor content and 11 matching normal pancreatic tissues, Table 1 and supplementary figure 1) using Nucleo Spin kit by Macherey-

Nagel (Düren, Germany) according to the manufacturer's instructions. For bisulfite conversion of gDNA the EZ DNA Methylation-Gold kit by Zymo Research Corporation (Freiburg, Germany) was used following the manufacturer's instructions.

Genomic DNA of 10 tumor samples was analyzed by its global methylation status using EpiSeeker methylated DNA Quantification Kit (ab117128, Abcam, Cambridge, United Kingdom), according to the supplier's instructions. Colorimetric measurements were done on an ELISA reader (Tecan, Männerdorf, Switzerland). Hyper-methylated and hypo-methylated DNAs (Zymo Research) were used as controls.

PCR and pyrosequencing investigation for *LINE-1* for 51 samples (GenBank accession number X58075) methylation analysis was performed using PyroMark kit (Qiagen, Hilden, Germany). To analyse sequence methylation of *LINE-1*, the PyroMark Q24 CpG LINE-1 (4x24) Methylation detection assay was used (Qiagen). Amplifications were performed with Master Mix PyroMark PCR Kit (Qiagen) according to supplier's instructions on a Veriti System gradient apparatus (Applied Biosystems, Thermo Fisher Scientific). PCR product was bound to Streptavidin Sepharose HP (Amersham Biosciences, GE Healthcare, Little Chalfont, United Kingdom), purified, washed, denatured and washed again with the PyroMark Q24 Vacuum Workstation 220V (Qiagen). Pyrosequencing was performed using the Qiagen PyroMark Q24 System with the pyromark Q24 Cartridge Method 0011 (Qiagen). The assay setups and analysis were performed with PyroMark Assay Design Software V.1.0.6 (Qiagen).

MGMT (O⁶-methylguanine-DNA-methyltransferase) promoter methylation was assessed in 25 tumor samples as previously described (Vassella, et al. 2011). Samples with methylation level higher and equal to 5% were considered hyper-methylated and samples with methylation level <5% were considered hypo-methylated.

The MEN1 gene was analysed in 26 tumor samples by semi-conductive sequencing using an Ion Torrent PGM (Life Technologies). Protein coding exons were amplified by multiplex polymerase chain reaction using 2 primer pools designed by the Ion AmpliSeq Designer (Life Technologies). Library construction, emulsion polymerase chain reaction, and sequencing were performed according to the manufacturer's recommendations. The Torrent Suite 5.0.3 platform was used for sequence alignment with the hg19 human genome reference. Variant calling was performed with the variant caller 5.0.3.5. and the IonReporter 5.0 software (Life Technologies, Grand Island, NY). The average base coverage depth for most samples was more than 2000 reads. MEN1 mutations found are summarized in table 1 in the Supplementary Material.

DAXX knock down

For virus infection 6×10^5 cells were seeded in 6 wells plate the day before. pLKO.1 lentiviral vectors expressing small hairpin (sh) RNAs targeting DAXX (Sh-DAXX_H2410: and Sh-DAXX_2503) or a nontargeting shRNA control (SHCOO2) were purchased from Sigma-Aldrich. Lentiviral production and transduction were done as described in (Tschan, et al. 2003). Transduced cells were selected by puromycin treatment ($1.5 \mu\text{g/ml}$, Invitrogen). For micro-nuclei counting, cells were seeded in 24-well plates on coverslips coated with FBS, 1×10^4 cells per well. Cells were fixed with 4% Paraformaldehyde for 30 min at room temperature. DAPI was used to stain nuclei. Micronuclei were counted under a fluorescent microscope (Axiophot2, Zeiss).

Viability and apoptosis assays

For MTT assay cells were seeded into 96-well plates at the density of 16'000 cells per well. After 24h medium was replaced by 100ul of medium with 10% MTT (0.5mg/ml final concentration) (Sigma-Aldrich) and incubate 1h at 37°. After incubation the medium was removed and 200 μl of DMSO (Sigma-Aldrich) and 25 μl of Sorensen solution (0.1M Glycine, 0.1M NaCl, pH 10.5 in

141 water) were added into each well. Absorbance at 570nm was determined on a spectrophotometer
142 (Tecan).

143 **Cell cycle analysis with FACS**

144 Briefly, cells were seeded 5×10^5 cells in duplicates or triplicates in 6-well plates. The day after
145 cells were treated with Nocodazol. After 16h of treatment cells were fixed in ice cold EtOH
146 overnight. PI staining was performed directly before measurement on BD-FACS LSR SorpII
147 using BD FACSDiva 6.1 software (BD Bioscience, Heidelberg, Germany). Results were
148 analyzed using FlowJo v9.8 software (TreeStar, USA).

149 **Protein extraction and Western blot analysis**

150 For western blotting Cells were cultivated in 6-well plates and lysate in Urea buffer. Forty ng
151 proteins were loaded on 4-20% Mini-PROTEAN® TGX Stain-Free™ Gel (Bio-Rad, Cressier,
152 Switzerland). Transfer was performed using transfer turbo blot system (Bio-Rad). Primary
153 monoclonal antibodies rabbit anti DAXX (clone 25C12, 1:1000 in 5% BSA, Cell signaling,
154 Cambridge, United Kingdom) and mouse anti human α -tubulin (clone B-5-1-2, 1:1000 in 5%
155 BSA, Sigma), GAPDH (clone 6c5, 1:1000 in 5% skimmed milk, Merk Millpore, Darmstadt,
156 Germany) were used. As secondary antibodies goat anti-rabbit DyLight® 650 conjugate
157 (LabForce, Muttenez, Switzerland) and goat anti-mouse DyLight® 550 conjugate (LabForce) both
158 diluted 1:500 in 5% milk were used. Signal was detected with ChemiDoc MP System (Bio-Rad)
159 and analyzed in ImageJ (freeware, 1.48v, Bethesda, USA). Protein levels were normalized to α -
160 tubulin, GAPDH or total protein.

Statistics

Statistical analysis was performed using GraphPAD prism 5 software (La Jolla, CA, USA). Statistical differences were calculated using unpaired two-tailed Student's t test. The χ^2 test or the Fisher exact test was used to calculate contingency tables. *P* values less than .05 were considered statistically significant.

Results

Ex-vivo analysis of human PanNET samples

DAXX and or ATRX negative PanNET are hypo methylated

In order to first assess whether DAXX/ATRX loss had an impact on the DNA methylation pattern we evaluated global DNA methylation on 10 PanNET samples. DNA extracted from 5 PanNET samples positive for DAXX/ATRX IHC staining, negative for ALT activation and CIN negative (DAXX/ATRX+/ALT-/CIN-) and from 5 PanNET samples negative for DAXX/ATRX staining, positive for ALT activation and CIN positive (DAXX/ATRX-/ALT+/CIN+) were analyzed for global DNA methylation with the colorimetric EpiSeeker assay (Methylated DNA Quantification Kit, Abcam). As shown in figure 1-A DAXX/ATRX-/ALT+/CIN+ tumors exhibit a significantly lower level of DNA methylation compared to DAXX/ATRX+/ALT-/CIN- ones ($p<0.01^{**}$), which is comparable to the un-methylated control. To confirm our findings in a larger setting and with an additional method, we stained 2 TMAs, composed as described in the material and methods section and in (Marinoni et al. 2014) with an anti-5-methylcytidine antibody (Eurogentec) that specifically recognizes the methylated base and does not cross-react with the un-methylated one. We obtained results on 153 samples; the characteristic of these samples is reported in table 1.

We observed that strong 5-methylcytidine staining associates with DAXX and ATRX proficient tumors while weak signal correlates with DAXX/ATRX deficient ones $p<0.05^*$ (Figure 1 B-G and Table 2), suggesting that DAXX/ATRX deficient tumor show global hypo-methylation compared to the positive ones. Normal islets showed a strong 5-methylcytidine staining (Figure 1 B-C).

To examine the DNA methylation level of non-coding regions we evaluated the (Long Interspersed Element) *LINE1* methylation status as a marker of global DNA methylation in 55 PanNET and 11 non-neoplastic pancreatic specimens, by pyro-sequencing (Qiagen). We observed that *LINE1* is hypo-methylated in PanNETs compared to normal pancreas ($p<0.001^{***}$) (Figure 2-A) as previously reported (Choi et al. 2007; Stefanoli et al. 2014). *LINE1* hypo-methylation indeed associates with CIN ($p<0.05^*$) (Figure 2-B), as we hypothesized. However, no differences in *LINE1* methylation were observed in either DAXX/ATRX positive and negative tumors, ALT positive and negative (Figure 2 C-E). In order to assess if MEN1 mutations impact on *LINE1* methylation levels we sequenced MEN1 gene in 26 samples. Eleven samples resulted to be mutated. The mutations found are summarized in Supplementary Material Table 1. No difference in *LINE1* methylation status were observed between mutant and wild type tumors (Figure 2 F). Interestingly, *LINE1* hypo-methylation predicts for shorter disease free survival ($p<0.05^*$), (figure 3 supplementary material) in agreement with the results reported by Stefanoli et al. (Stefanoli et al. 2014); while no differences in survival are detectable in tumors positive and negative for 5-methylcytidine staining (data not shown).

We performed quantitative methylation specific PCR to assess whether *LINE1* hypo-methylation or DAXX/ATRX loss correlate with hyper-methylation of MGMT promoter, due to its clinical relevance. We found 8 samples with MGMT promoter hyper-methylated and 17 samples where MGMT promoter was un-methylated. No correlation between *LINE1* hypo-methylation or

DAXX/ATRX loss and MGMT methylation level was found (Supplementary Figure 4), suggesting two independent mechanisms for the two events, as previously proposed (Stefanoli et al. 2014).

In vitro upon DAXX knock-down

Induction of genomic instability and G1 arrest

In order to assess if DAXX loss is sufficient to induce genomic instability, we knocked down DAXX in two PanNET cell lines, QGP-1 and BON-1 by Lentiviral transduction of SH-RNAs. DAXX knock down was evaluated by western blotting 9, 17 and 24 days after lentiviral infection. Two different DAXX specific vectors (1 and 2) and scramble control were used in both cell lines. DAXX expression is highly reduced after 9 days from infections in both cell lines (Figure 3-A and supplementary material Figure 5-A). After 17 days DAXX expression is down-regulated to a lesser extent while both cell lines re-express DAXX after 24 days. Therefore, all experiments were performed within the first 10 days after infection. Of note, the knock down efficiency was higher with vector SH-DAXX-1 than SH-DAXX-2; consistently we observed a stronger phenotype on the cells transduced with the first vector.

Interestingly, we observed that in QGP-1 cells DAXX knock down induced an increased number of micronuclei formation and anaphase bridges while no micro-nuclei formation was observed in BON-1 cells. DAXX knock down QGP-1 cells showed an increased number of micronuclei formation compared to scramble (Figure 3 B-D). This result suggests an increased genomic instability induced by DAXX loss in QGP-1 cells.

DAXX knock down in both QGP-1 and BON-1 does not induce ALT activation as detected by telomere FISH *in vitro* (data not shown), similarly to what has been shown by others in ATRX knock down cells (Napier, et al. 2015).

DAXX knock down reduced cell viability, measured by MTT assay (Figure 3-E and supplementary material Figure 5-B), indicating that DAXX has not a classical tumor suppressor gene function. No significant increase in apoptosis was observed in DAXX knock down samples compared to the scramble control (Supplementary Figure 6). FACS analysis revealed that DAXX knock down induces G1 arrest in both BON-1 cells and QGP-1 (Figure 3-F and Supplementary Figure 7).

Short time DAXX knock down does not affect *LINE1* and global methylation.

Since in human samples we observed that DAXX and or ATRX loss correlates with DNA hypomethylation we wanted to investigate whether DAXX knock down impairs DNA methylation *in vitro* as well. No difference in *LINE1* methylation as well as global methylation were observed after 10 days of DAXX knock down in both BON-1 and QGP-1 cells (Supplementary Figure 8 and data not shown). Similarly, no difference in MGMT promoter methylation were observed upon DAXX knock down (data not shown).

Discussion

The sequence of the events and the mechanism by which DAXX and or ATRX loss induces ALT and CIN are still unknown. Here we provide evidence, that epigenetic mechanisms could be involved in this process. In detail, we showed by immunohistochemistry and biochemical methods that DAXX and or ATRX negative PanNET are globally hypo-methylated. Hypomethylation of repeated sequences has been described in several cancers in correlation with progressive increase of the grade of malignancy (Ehrlich 2002). Long interspersed nuclear elements (*LINE1*) are the most abundant mobile DNAs in the human genome and hypomethylation of these sequences has been shown in different type of cancer including PanNETs

(Choi et al. 2007; Stefanoli et al. 2014). Indeed, we could confirm that *LINE1* is hypo-methylated in PanNET compared to normal pancreas. Here we additionally showed that PanNETs showing CIN have a lower level of *LINE1* methylation than chromosomally stable PanNET. We previously showed that DAXX and or ATRX loss in PanNETs correlates with CIN (Marinoni et al. 2014). We hypothesize that DAXX and ATRX loss in PanNET cells result in a decreased DNA methylation thus promoting CIN. Indeed, we found that DAXX/ATRX negative PanNET show lower level of global methylation assessed by IHC and by a colorimetric assay.

However, we could not find a correlation between DAXX and or ATRX loss, ALT activation and *LINE1* methylation. *LINE1* methylation could therefore be mediated by other unknown events. On the other hand, a multi-step model in which DAXX and ATRX loss progressively impairs DNA methylation and chromatin structure would also explain this discrepancy. Indeed, our cell line results could point into this direction: Short time DAXX knock down did not induce any changes in global or *LINE1* DNA methylation. Either DAXX knock down is not sufficient to induce global hypo-methylation without other events, or it is instead a matter of time and additional cell cycles are needed.

Impairment of DNA methylation, particularly at telomeres has been described in glioblastoma with ALT activation as well as in Astrocytoma with low ATRX expression (Cai, et al. 2015; Sturm, et al. 2012). Recently it has been shown that DAXX deficient PanNET showed higher methylation variation compared to ATRX negative ones (Pipinikas et al. 2015). However this report did not focus on global methylation levels, which could largely be influenced by non-coding sequences, such as *LINE1* and telomeric regions.

A reduction of methylation in the subtelomeric regions, allowing DNA recombination, might also promote ALT activation (Gonzalo et al. 2006). Upon DAXX knock-down in PanNET cell lines we did not observed ALT activation, in keeping with other finding showing that DAXX and

280 ATRX loss does not induce ALT activation *in vitro* in telomerase positive cells (Napier et al.
281 2015). In QGP-1 cells we observed a higher number of micronuclei upon DAXX knock down
282 compared to control which might be a sign of increased genomic instability already at this short
283 time-point and without ALT phenotype and impairment in DNA methylation. However, the small
284 percentage, of cells showing micro nuclei formation upon DAXX knock out might not be
285 sufficient to detect DNA methylation changes when this is assessed in the whole cell population.
286 The phenotype of DAXX knock down cells has confirmed the non-conventional tumor
287 suppressor role. DAXX silencing *in vitro* in BON-1 and QGP-1 cells induced G1/G0 cell cycle
288 arrest. Similarly, ATRX knock down in other tumor models reduced cell proliferation and
289 induced genomic instability (Cai et al. 2015; Huh, et al. 2016; Huh, et al. 2012; Lovejoy, et al.
290 2012). It is important to point out that BON-1 and QGP-1 cells are mainly a model for G3
291 PanNECs with mutations in genes, which are usually not altered in G1-G2 PanNETs (i.e. *TP53*)
292 (Vandamme, et al. 2015). In this context DAXX knock down may impact on the cell cycle
293 regulation and genomic instability differently than in the slow progressive tumors with a different
294 mutational spectrum. Additionally the difference in the mutations background between QGP-1
295 and BON-1 may explain the different results in the micronuclei formation. Recently it has been
296 shown that Daxx knock-down in a rat insulinoma cell line increased cell proliferation, suggesting
297 that this model might be more appropriate for Daxx functional studies (Feng, et al. 2016).
298 However rodent cells usually show minor and different genomic instability pattern compared to
299 human cells and they rarely activate ALT mechanism for telomeres lengthening, even in absence
300 of telomerase (Hermsen, et al. 2015) (Argilla, et al. 2004). This suggests that even this model
301 harbours some limitation in the study of DAXX loss impact on genomic instability, ALT
302 activation and DNA methylation which was the main focus of our work.

Our finding very likely only show a part of a more complex situation as other factors than DAXX and ATRX mutation can influence the epigenetic status. DAXX and or ATRX loss is frequently accompanied by *MEN1* mutations and this possibly contributes to the epigenetic status. MEN1 is mutated in almost 44% of sporadic PanNETs (Jiao et al. 2011). *MEN1* gene, encodes the transcription factor menin, which recruits the H3K4me3 histone methyltransferase mixed lineage leukaemia (MLL1) complex that plays an essential role in chromatin remodelling and gene expression (Agarwal, et al. 1999; Agarwal and Jothi 2012; Yang, et al. 2013). However MEN1 mutations in PanNETs are not associated with CIN nor with ALT phenotype. In agreement with a model of epigenetically induced CIN, our results showed no correlation between LINE1 methylation level and MEN1 mutation status. Similarly we did not detect any correlation between global methylation assessed by IHC and MEN1 mutations (data not shown).

In conclusion our data provide evidence that DAXX and ATRX loss impact on global DNA methylation of PanNETs cells, which seem to be involved in chromosomal instability. This could enable PanNET to acquire clonal heterogeneity leading to a selection of more aggressive clones.

Declaration of interest

The authors disclose no potential conflicts of interested.

Author contributions

Ilaria Marinoni: experimental design, supervision and execution of *in vitro* and ex-vivo experiments, manuscript writing.

Astrid Wiederkeher: execution of the *in vitro* experiments

Tabea Wiedmer: execution of the FACS analysis and critical reading of the manuscript

Sophia Pantasis: *LINE1* pyrosequencing.

Rasmus Frank: *LINE1* pyrosequencing and MGMT methylation.

Annunziata Di Domenico: DNA extraction and samples collection.
Erik Vassella: MEN1 sequencing and MGMT methylation analysis.
Anja Schmitt: Acquisition of clinical data and critical reading of the manuscript
Aurel Perren: experimental design, data acquisition of ex-vivo experiments, morphological analysis and manuscript writing.

Funding

The Study was supported by the Swiss National Science foundation (SNF Grant No. 310030_144236 to Aurel Perren and SNF-Marie Heim Vögtlin (PMPDP3_164484/1) to Ilaria Marinoni) and by Tumor Forschung Bern to Ilaria Marinoni.

Acknowledgment

We would like to thank Prof. Mario Tschan for the Lentivirus plasmids and for the support with all the Lentivirus experiments. Cornelia Schlup for the support with NGS and Pyrosequencing. The Translation Research Unit and in particular Dr. Jose Galvanez for cutting the slides and the Immuno Histo Chemistry. Tissues were provided with support of the Tissue Bank Bern (TBB).

Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Sagggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, et al. 1999 Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. *Cell* **96** 143-152.
Agarwal SK & Jothi R 2012 Genome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors. *PLoS One* **7** e37952.
Argilla D, Chin K, Singh M, Hodgson JG, Bosenberg M, de Solorzano CO, Lockett S, DePinho RA, Gray J & Hanahan D 2004 Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. *Cancer Cell* **6** 373-385.
Cai J, Chen J, Zhang W, Yang P, Zhang C, Li M, Yao K, Wang H, Li Q, Jiang C, et al. 2015 Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. *Oncotarget*. **6** 18105-15.
Choi IS, Estecio MR, Nagano Y, Kim do H, White JA, Yao JC, Issa JP & Rashid A 2007 Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). *Mod Pathol* **20** 802-810.
Das PM & Singal R 2004 DNA methylation and cancer. *J Clin Oncol* **22** 4632-4642.
Ehrlich M 2002 DNA methylation in cancer: too much, but also too little. *Oncogene* **21** 5400-5413.
Feng Z, Wang L, Sun Y, Jiang Z, Domsic J, An C, Xing B, Tian J, Liu X, Metz DC, et al. 2016 Menin and Daxx Interact to Control Neuroendocrine Tumors via Epigenetic Regulation of Membrane Metallo-Endopeptidase. *Cancer Res* [Epub ahead of print].

363 Gonzalo S, Jaco I, Fraga MF, Chen T, Li E, Esteller M & Blasco MA 2006 DNA methyltransferases control
 364 telomere length and telomere recombination in mammalian cells. *Nat Cell Biol* **8** 416-424.
 365 Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG,
 366 Hebbar S, et al. 2011 Altered telomeres in tumors with ATRX and DAXX mutations. *Science* **333** 425.
 367 Hermesen R, Toonen P, Kuijk E, Youssef SA, Kuiper R, van Heesch S, de Bruin A, Cuppen E & Simonis M
 368 2015 Lack of major genome instability in tumors of p53 null rats. *PLoS One* **10** e0122066.
 369 House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A
 370 & Yeo CJ 2003 Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine
 371 neoplasms. *Ann Surg* **238** 423-431; discussion 431-422.
 372 Huh MS, Ivanochko D, Hashem LE, Curtin M, Delorme M, Goodall E, Yan K & Picketts DJ 2016 Stalled
 373 replication forks within heterochromatin require ATRX for protection. *Cell Death Dis* **7** e2220.
 374 Huh MS, Price O'Dea T, Ouazia D, McKay BC, Parise G, Parks RJ, Rudnicki MA & Picketts DJ 2012
 375 Compromised genomic integrity impedes muscle growth after Atrx inactivation. *J Clin Invest* **122** 4412-
 376 4423.
 377 Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, et
 378 al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic
 379 neuroendocrine tumors. *Science* **331** 1199-1203.
 380 Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, et
 381 al. 2012 Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the
 382 alternative lengthening of telomeres pathway. *PLoS Genet* **8** e1002772.
 383 Malpeli G, Amato E, Dandrea M, Fumagalli C, Debattisti V, Boninsegna L, Pelosi G, Falconi M & Scarpa A
 384 2011 Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic
 385 endocrine tumors. *BMC Cancer* **11** 351.
 386 Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ &
 387 Perren A 2014 Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival
 388 of Patients With Pancreatic Neuroendocrine Tumors. *Gastroenterology* **146** 453-460 e455.
 389 Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA & Reddel RR 2015 ATRX
 390 represses alternative lengthening of telomeres. *Oncotarget* **6** 16543-58.
 391 Noh KM, Allis CD & Li H 2016 Reading between the Lines: "ADD"-ing Histone and DNA Methylation Marks
 392 toward a New Epigenetic "Sum". *ACS Chem Biol* **11** 554-563.
 393 Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T,
 394 et al. 2015 Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine
 395 tumours. *Endocr Relat Cancer* **22** L13-18.
 396 Puto LA & Reed JC 2008 Daxx represses RelB target promoters via DNA methyltransferase recruitment
 397 and DNA hypermethylation. *Genes Dev* **22** 998-1010.
 398 Schmitt AM, Pavel M, Rudolph T, Dawson H, Blank A, Komminoth P, Vassella E & Perren A 2014
 399 Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic
 400 Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology* **100** 35-44.
 401 Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Kloppel G, Moch H, Heitz PU, Komminoth P &
 402 Perren A 2009 VHL inactivation is an important pathway for the development of malignant sporadic
 403 pancreatic endocrine tumors. *Endocr Relat Cancer* **16** 1219-1227.
 404 Stefanoli M, La Rosa S, Sahnane N, Romualdi C, Pastorino R, Marando A, Capella C, Sessa F & Furlan D
 405 2014 Prognostic Relevance of Aberrant DNA Methylation in G1 and G2 Pancreatic Neuroendocrine
 406 Tumors. *Neuroendocrinology* **100** 26-34.
 407 Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M,
 408 Bender S, et al. 2012 Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological
 409 subgroups of glioblastoma. *Cancer Cell* **22** 425-437.

Tschan MP, Fischer KM, Fung VS, Pirnia F, Borner MM, Fey MF, Tobler A & Torbett BE 2003 Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. *J Biol Chem* **278** 42750-42760.

Vandamme T, Peeters M, Dogan F, Pauwels P, Van Assche E, Beyens M, Mortier G, Vandeweyer G, de Herder W, Van Camp G, et al. 2015 Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. *J Mol Endocrinol* **54** 137-147.

Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V & Mariani L 2011 Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. *J Neurooncol* **104** 293-303.

Yang YJ, Song TY, Park J, Lee J, Lim J, Jang H, Kim YN, Yang JH, Song Y, Choi A, et al. 2013 Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. *Cell Death Dis* **4** e583.

Figure legends:

Figure 1: Global methylation in PanNETs. A) Global methylation levels of DNA isolated from human PanNETs using EpiSeeker methylated DNA Quantification Kit (Abcam). Highly methylated DNA and unmethylated DNA were used as controls. DAXX/ATRX-/ALT+/CIN+ tumors showed hypo-methylation compared to DAXX/ATRX+/ALT-/CIN- ones ($p<0.01^{**}$). B-G) IHC with anti-5-methylcytidine antibody (Millipore) on human tissues. (B-C) Normal pancreas: (*) pancreatic islets and (**) exocrine pancreas. D-E two PanNETs samples showing low 5-methylcytidine expression and F-G two PanNET samples showing high 5-methylcytidine expression.

Figure 2: LINE-1 methylation in PanNETs. A) PanNET samples showed a significant lower level of methylation compared to normal surrounding tissues ($p<0.001^{*}$). B) PanNETs with high CIN showed a lower level of LINE1 methylation ($p<0.05$) compared to tumors with no CIN. C-D) DAXX/ATRX- tumors and ALT+ tumors do not show difference in LINE1 methylation compared to respectively DAXX/ATRX+ and ALT- tumors. E) Tumors which are both DAXX/ATRX- and ALT+ did not show difference in LINE1 methylation level compared to tumors, which are DAXX/ATRX+ and ALT-, F) MEN1 mutated and wild type PanNET do not show differences in LINE1 methylation levels.

440

441 **Figure 3: DAXX knock-down in QGP-1 cell lines.** A) Western blotting showing DAXX knock-

442 down after 9, 17 and 24 days upon infection with two different plasmids SH-DAXX-1 and SH-

443 DAXX-2 in QGP-1. Parental (Par.) cells and cells transduced with scramble vector (Scr.) were

444 used as controls. DAXX expression comes back to normal level after 24 days from the infection.

445 Quantification of the knock-down after 9 and 17 days from infection was based on three different

446 experiments. B) DAPI staining of QGP-1 cells after DAXX knock-down; arrows indicate an

447 anaphase bridge and micronuclei. C) Fold changes of the number of micronuclei (MN) per cells

448 compare to scramble. D) Number of anaphase bridges compare to mitosis. SH-DAXX-1 and SH-

449 DAXX-2 cells showed an increased on micronuclei and anaphase bridges compared to controls.

450 E) Graphic representation of MTT viability assays after 8 days and after 16 days from infection.

451 DAXX knock-down impairs cell viability. After 16 days when DAXX expression is restored to

452 normal levels, the cells proliferate as the controls, suggesting a direct effect of DAXX on cell

453 viability. F) FACS analysis of QGP1 cells after DAXX knock-down. Cells knocked-down for

454 DAXX showed an increased in the percentage of cells in G1/G0 compared controls. The results

455 are based on at least three repetitions.

456




Figure 1

192x97mm (300 x 300 DPI)




Figure 2

143x101mm (300 x 300 DPI)




Figure 3

287x417mm (300 x 300 DPI)

Table 1: Characteristics of the human sample collective

Collective	Total patients (IHC plus <i>LINE1</i> and Global methylation)	IHC	<i>LINE1</i> and global methylation
Tot	167	153	55
Female	82	75	26
Male	83	76	28
	2	2	1
Age average	56,66	56,09	55,21
G1	119	107	33
G2	48	46	22
T1	61	53	13
T2	46	44	18
T3-4	45	41	23
n.a.	15	15	1
N0	58	54	15
N1	39	36	24
n.a.	70	63	16
M0	95	85	34
M1	30	30	12
n.a.	42	38	9
DAXX/ATRX +	74	67	13
DAXX/ATRX-	47	44	30
n.a.	46	42	12
DAXX-	23	23	3
DAXX+	106	97	38
n.a.	38	33	14
ATRX-	28	25	13
ATRX+	95	88	33
n.a.	44	40	9
ALT-	59	53	16
ALT+	39	37	20
n.a.	69	63	19
CIN-	22	15	11
CIN+	30	26	11
n.a.	115	112	33
<i>MEN1</i> wt	15	15	15
<i>MEN1</i> mut	11	11	11
n.a.	141	127	29
MGMT hyper			8
MGMT hypo			17
			30
RFS (months)		52 (data based on 44 patients)	
TSS (months)		80 (data based on 44 patients)	

Table legend: G (Grade), T (Tumor Stage), N (lymph node metastasis), M (Distant Metastasis) ALT (Alternative Lengthening Telomeres), CIN (Chromosomal Instability), RFS (Relapse free Survival), TSS (Tumor Specific Survival).

Table 2: Correlation between DAXX/ATRX expression and 5-methylcytidine staining in human PanNET tissues.

	Low 5-metyl-cytidine	High 5-metyl-cytidine	p value
DAXX/ATRX-	28	15	0.019*
DAXX/ATRX+	28	39	
DAXX-	17	6	0.020*
DAXX+	44	52	
ATRX-	15	13	0.517
ATRX+	40	48	
ALT-	25	28	0.338
ALT+	21	15	